当前位置：首页 SCI期刊 SCIE期刊医学中科院4区 JCRQ2 期刊介绍(非官网)

Hematological OncologySCIE

国际简称：HEMATOL ONCOL 参考译名：血液肿瘤学

中科院分区
4区
CiteScore分区
Q2
JCR分区
Q2

基本信息：: ISSN：0278-0232; E-ISSN：1099-1069; 是否OA：未开放; 是否预警：否; TOP期刊：否

出版信息：: 出版地区：ENGLAND; 出版商：John Wiley and Sons Ltd; 出版语言：English; 出版周期：Quarterly; 出版年份：1983; 研究方向：血液学-医学

评价信息：: 影响因子：3.3; H-index：42; CiteScore指数：4.2; SJR指数：0.82; SNIP指数：0.717

发文数据：: Gold OA文章占比：30.61%; 研究类文章占比：65.59%; 年发文量：93; 自引率：0.0606...; 开源占比：0.1672; 出版撤稿占比：0; 出版国人文章占比：0.09; OA被引用占比：0.1165...

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介Hematological Oncology期刊介绍

Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:

-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders

-Diagnostic investigations, including imaging and laboratory assays

-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases

-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies

-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.

Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.

期刊简介Hematological Oncology期刊介绍

《Hematological Oncology》自1983出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间： 12周，或约稿
医学
HEMATOLOGY
SCIE
中科院4区
非预警

Cite Score数据（2024年最新版）Hematological Oncology Cite Score数据

CiteScore：4.2
SJR：0.82
SNIP：0.717

学科类别	分区	排名	百分位
大类：Medicine 小类：Hematology	Q2	65 / 137	52%
大类：Medicine 小类：Oncology	Q2	197 / 404	51%
大类：Medicine 小类：Cancer Research	Q3	146 / 230	36%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Hematological Oncology 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	4区	HEMATOLOGY 血液学 ONCOLOGY 肿瘤学	4区 4区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Hematological Oncology JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：HEMATOLOGY	SCIE	Q2	30 / 97	69.6%
学科：ONCOLOGY	SCIE	Q2	118 / 322	63.5%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：HEMATOLOGY	SCIE	Q3	49 / 97	50%
学科：ONCOLOGY	SCIE	Q3	212 / 322	34.32%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
Italy100
USA62
Japan48
CHINA MAINLAND45
Switzerland31
France26
GERMANY (FED REP GER)23
Israel17
Brazil13
England13

本刊中国学者近年发表论文

1、Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system
Author: Li, Xingying; Yu, Hui; Fu, Xiaorui; Zhang, Lei; Li, Xin; Li, Ling; Wang, Xinhua; Sun, Zhenchang; Zhang, Xudong; Li, Zhaoming; Wu, Jingjing; Chang, Yu; Yan, Jiaqin; Zhou, Zhiyuan; Nan, Feifei; Wu, Xiaolong; Tian, Li; Zhang, Mingzhi

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 267-274. DOI: 10.1002/hon.2894
2、Primary treatment and recent survival trends in patients with primary diffuse large B-cell lymphoma of central nervous system, 1995-2016: A population-based SEER analysis
Author: Chen, Cui; Sun, Peng; Sun, Xiao-Qing; Chen, Shao-Yong; Yang, Hang; Wang, Yu; Li, Zhi-Ming

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 248-256. DOI: 10.1002/hon.2918
3、Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis
Author: Lang, Mingxiao; Feng, Youqin; Meng, Xiangrui; Zhao, Jing; Song, Zheng; Qian, Zhengzi; Qiu, Lihua; Zhou, Shiyong; Liu, Xianming; Li, Lanfang; Yang, Haiyan; Song, Yuqin; Li, Wei; Zhang, Huilai

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 239-247. DOI: 10.1002/hon.2928
4、Review on natural killer/T-cell lymphoma
Author: He, Xiaohua; Gao, Yan; Li, Zhiming; Huang, Huiqiang

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 221-229. DOI: 10.1002/hon.2944
5、Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma
Author: Song, Wenting; Chen, Zhan; Shi, Cunzhen; Gao, Yuyang; Feng, Xiaoyan; Li, Hongwen; Li, Zhaoming; Zhang, Mingzhi

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 257-266. DOI: 10.1002/hon.2954
6、TAFRO syndrome with fatigue and abdominal distension as the first symptom: A case report
Author: Zhou, Bai; Tang, Chao; Chen, Guiyang; Jiang, Tiebin; Shi, Xiao; Wang, Fen

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 285-290. DOI: 10.1002/hon.2962
7、Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden
Author: Mu, Juan; Deng, Haobin; Lyu, Cuicui; Yuan, Jijun; Li, Qing; Wang, Jia; Jiang, Yanyu; Deng, Qi; Shen, Jichun

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 275-284. DOI: 10.1002/hon.2981
8、Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma
Author: Li, Xiao; Liu, Mengke; Shi, Qing; Fang, Ying; Fu, Di; Shen, Zhi-xiang; Yi, Hongmei; Wang, Li; Zhao, Weili

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 230-238. DOI: 10.1002/hon.2993